Acamprosate calcium - CAS 77337-73-6
Catalog number: 77337-73-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C10H20CaN2O8S2
Molecular Weight:
400.48
COA:
Inquire
Targets:
GABA Receptor
Description:
Acamprosate calcium is a gamma-aminobutyric acid(GABA)agonist and modulator of glutamatergic systems. It has been used in alcohol dependence treatments and may be an effective augmentation therapy in patients with treatment-resistant anxiety. It has low bioavailability, but also has an excellent tolerability and safety profile. It is unique in that it is not metabolized by the liver and is also not impacted by alcohol use, so it can be administered to patients with hepatitis or liver disease and to patients who continue drinking alcohol. It was approved for use in the therapy of alcohol dependence and abuse in the United States in 2004.
Purity:
>98.0%
Appearance:
White to off-white solid
Synonyms:
Calcium 3-acetamidopropane-1-sulfonate;Calcium 3-(acetylamino)propanesulphonate;3-(Acetylamino)-1-propanesulfonic Acid Calcium Salt;Calcium Acetylhomotaurine ;Alcomed;Sobriol;Aotal calcium;Calcium N-acetylhomotaurinate
Solubility:
10 mM in H2O (free soluble)
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
Acamprosate calcium has been used in alcohol dependence treatments and may be an effective augmentation therapy in patients with treatment-resistant anxiety. It has low bioavailability, but also has an excellent tolerability and safety profile. It is unique in that it is not metabolized by the liver and is also not impacted by alcohol use, so it can be administered to patients with hepatitis or liver disease and to patients who continue drinking alcohol.
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Grams to Kilograms
Melting Point:
270 °C
InChIKey:
BUVGWDNTAWHSKI-UHFFFAOYSA-L
InChI:
InChI=1S/2C5H11NO4S.Ca/c2*1-5(7)6-3-2-4-11(8,9)10;/h2*2-4H2,1H3,(H,6,7)(H,8,9,10);/q;;+2/p-2
Canonical SMILES:
CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]
Current Developer:
It has been approved the listing.
1.Modulation of learning and memory by natural polyamines.
Guerra GP1, Rubin MA2, Mello CF3. Pharmacol Res. 2016 Mar 22. pii: S1043-6618(16)30189-X. doi: 10.1016/j.phrs.2016.03.023. [Epub ahead of print]
Spermine and spermidine are natural polyamines that are produced mainly via decarboxylation of l-ornithine and the sequential transfer of aminopropyl groups from S-adenosylmethionine to putrescine by spermidine synthase and spermine synthase. Spermine and spermidine interact with intracellular and extracellular acidic residues of different nature, including nucleic acids, phospholipids, acidic proteins, carboxyl- and sulfate-containing polysaccharides. Therefore, multiple actions have been suggested for these polycations, including modulation of the activity of ionic channels, protein synthesis, protein kinases, and cell proliferation/death, within others. In this review we summarize these neurochemical/neurophysiological/morphological findings, particularly those that have been implicated in the improving and deleterious effects of spermine and spermidine on learning and memory of naïve animals in shock-motivated and nonshock-motivated tasks, from a historical perspective.
2.Potential Medications for the Treatment of Alcohol Use Disorder: An Evaluation of Clinical Efficacy and Safety.
Litten RZ1, Wilford BB2, Falk DE1, Ryan ML1, Fertig JB1. Subst Abus. 2016 Feb 29:0. [Epub ahead of print]
Alcohol use disorder (AUD), as currently defined in the Diagnostic and Statistical Manual, Fifth Edition (DSM-5), is a heterogeneous disorder stemming from a complex interaction of neurobiological, genetic, and environmental factors. As a result of this heterogeneity, there is no one treatment for AUD that will work for everyone. During the past two decades, efforts have been made to develop a menu of medications to give patients and clinicians more choices when seeking a therapy that is both effective and which has limited side effects. To date, three medications have been approved by the U.S. Food and Drug Administration (FDA) to treat alcohol dependence: disulfiram, naltrexone, and acamprosate. In addition to these approved medications, researchers have identified new therapeutic targets and, as a result, a number of alternative medications are now being evaluated for treatment of AUD in human studies. Although not approved by the FDA for the treatment of AUD, in some cases, these alternative medications are being used off-label by clinicians for this purpose.
3.Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence.
Sinclair JM1,2, Chambers SE3, Shiles CJ3,4, Baldwin DS3,5. Drug Saf. 2016 Mar 29. [Epub ahead of print]
Alcohol use disorders (AUD) cause significant morbidity and mortality worldwide, but pharmacological treatments for them are underused, despite evidence of efficacy. Acamprosate, naltrexone, nalmefene and disulfiram are all approved in one or more region for the treatment of AUD. Baclofen currently has a temporary indication in France. Safety considerations for using psychopharmacological treatments in this patient group include the impact of concurrent alcohol consumption at high levels; multiple physical comorbidities that may interfere with pharmacological effects, distribution and metabolism; and concomitant medication for the treatment of comorbid physical and psychiatric conditions. The five drugs, including an extended-release injectable suspension of naltrexone, have different safety profiles that need to be balanced with the treatment objective (initiation or continuation of abstinence, or reduction of drinking), individual patient preferences and comorbid conditions.
4.Alcoholic liver disease and hepatitis C virus infection.
Novo-Veleiro I1, Alvela-Suárez L1, Chamorro AJ1, González-Sarmiento R1, Laso FJ1, Marcos M1. World J Gastroenterol. 2016 Jan 28;22(4):1411-20. doi: 10.3748/wjg.v22.i4.1411.
Alcohol consumption and hepatitis C virus (HCV) infection have a synergic hepatotoxic effect, and the coexistence of these factors increases the risk of advanced liver disease. The main mechanisms of this effect are increased viral replication and altered immune response, although genetic predisposition may also play an important role. Traditionally, HCV prevalence has been considered to be higher (up to 50%) in alcoholic patients than in the general population. However, the presence of advanced alcoholic liver disease (ALD) or intravenous drug use (IDU) may have confounded the results of previous studies, and the real prevalence of HCV infection in alcoholic patients without ALD or prior IDU has been shown to be lower. Due to the toxic combined effect of HCV and alcohol, patients with HCV infection should be screened for excessive ethanol intake. Patients starting treatment for HCV infection should be specifically advised to stop or reduce alcohol consumption because of its potential impact on treatment efficacy and adherence and may benefit from additional support during antiviral therapy.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related GABA Receptor Products


CAS 155569-91-8 Emamectin Benzoate

Emamectin Benzoate
(CAS: 155569-91-8)

Emamectin Benzoate is the Emamectin derivative. Emamectin, also called as Proclaim, is widely used as an insecticide because of its chloride channel activation ...

CAS 91917-65-6 Ro 15-4513

Ro 15-4513
(CAS: 91917-65-6)

Ro 15-4513, a high affinity benzodiazepine ligand, acts as a competitive antagonist, and can therefore be an antidote to the acute impairment caused by alcohol....

CAS 602-41-5 Thiocolchicoside

Thiocolchicoside
(CAS: 602-41-5)

Thiocolchicoside is a semi-synthetic derivative of colchicine, an anti-inflammatory glycoside extracted from the flower seeds of superba gloriosa. Thiocolchicos...

CAS 157604-55-2 (S)-SNAP 5114

(S)-SNAP 5114
(CAS: 157604-55-2)

(S)-SNAP 5114 is a GABA transport inhibitor, displaying selectivity for GAT-3 and GAT-2 (IC50 = 5, 21 and 388 μM for hGAT-3, rGAT-2 and hGAT-1, respectively). (...

CAS 149184-22-5 CGP 55845 hydrochloride

CGP 55845 hydrochloride
(CAS: 149184-22-5)

CGP 55845 hydrochloride is a potent and selective GABAB receptor antagonist (IC50 = 5 nM), which prevents agonist binding (pKi = 8.35) and inhibits release of G...

CAS 951654-29-8 2-{3-[5-(2-Hydroxypropan-2-yl)-1H-1,3-benzodiazol-1-yl]phenyl}benzamide

2-{3-[5-(2-Hydroxypropan-2-yl)-1H-1,3-be
(CAS: 951654-29-8)

A GABAA receptor modulator that effects against anxiety.

CAS 85118-33-8 THIP hydrochloride

THIP hydrochloride
(CAS: 85118-33-8)

THIP hydrochloride is a GABAA receptor agonist and GABAA-ρ receptor antagonist. THIP exhibits antinociceptive, anticonvulsant and sedative effects. It is used a...

CAS 56189-68-5 CGP 13501

CGP 13501
(CAS: 56189-68-5)

CGP 13501 is a positive allosteric modulator of GABAB receptors, potentiating the effects of GABA at this receptor type.

Chemical Structure

CAS 77337-73-6 Acamprosate calcium

Quick Inquiry

Verification code

Featured Items